# Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

> **NCT03797326** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 611 (actual)

## Conditions studied

- Advanced Solid Tumors
- Triple Negative Breast Cancer
- Ovarian Cancer
- Gastric Cancer
- Colorectal Cancer
- Glioblastoma
- Biliary Tract Cancers
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03797326
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797326, "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03797326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*